醫藥股隨A股同業受捧 藥明康德、信達、康方、榮昌及開拓漲近9.5%-24%
中證監重申會嚴懲操縱市場惡意做空,加上中央匯金擴大ETF增持範圍,滬指及深成午後升幅曾擴至逾3%-6%,分別高見2,802及8,471。恆指及國指均突破重越10天及20天線,午後高見16,116及5,459,現報16,107及5,442,急漲597點或近3.9%及236點或4.5%,總成交額960億元。
內地生物疫苗及醫藥生物板塊均急漲7%-7.6%。本港醫藥板塊也不甘寂寞,尤其是開拓藥業(09939.HK)高見1.98元,現報1.87元,急升近24%。榮昌生物(09995.HK)重越10天線,最高見18.36元,現報17.88元,急漲16%;康方生物(09926.HK)重越100天線,報43.1元,急漲近11%。信達生物(01801.HK)重越10天線,現報33.05元,急漲近10%。騰盛博藥(02137.HK)高見1.84元,現報1.77元,急漲9.9%。
藍籌翰森(03692.HK)高見12.84元,現報12.82元,急升9.8%。金斯瑞(01548.HK)高見14.12元,現報13.96元,漲8.9%。君實生物(01877.HK)升逾7%股價曾高見12.36元。
藍籌藥明康德(02359.HK)高見49.95元,現報49.7元,續升9.4%;藥明康德A(603259.SH)漲逾7%曾高見51.12元人民幣。
凱萊英(06821.HK)重越10天線,高見66.4元,現報65.85元,急升8%;凱萊英A(002821.SZ)升近6%曾高見89.84元民幣。
康希諾生物(06185.HK)升7.6%報16.64元;康希諾A(688185.SH)漲逾9%報50.3元人民幣。
復星醫藥(02196.HK)由逾十年低位連升第二天,現報14.04元,續升近6%;復星醫藥A(600196.SH)漲8.5%報22.99元人民幣。
藥明合聯(02268.HK)、藥明生物(02269.HK)、來凱醫藥-B(02105.HK)、藍籌國藥(01099.HK)、艾美疫苗(06660.HK)、聯邦制藥(03933.HK)、中生(01177.HK)及石藥(01093.HK)升近4%-6.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.